We provided comprehensive engineering and design services for a 65,000-square-foot expansion of vaccine manufacturing operations to meet increasing demand and stringent regulatory standards.

The upgraded facility will feature advanced biosafety level 2 (BSL-2) and occupational exposure limits (OEL) 10 to 100 g/m3 containment standards, solvent-based formulation, aseptic vial filling, two lyophilizers, and cold-storage capabilities. It will also include a high-speed packaging line, automated visual inspection and comprehensive cold chain packaging, all designed for compliance with European Union Good Manufacturing Practices (GMPs).

Increasing demand meant that the existing vaccine manufacturing operations were no longer sufficient. The project was the largest capital investment to date for the owner and a strategic shift in its vaccine manufacturing capabilities, backed by funding from the Biomedical Advanced Research and Development Authority (BARDA) in response to urgent public health readiness needs.

From regulatory readiness to sustainability and operational uptime, this expansion illustrates our ability to deliver fully integrated, compliant and future-focused solutions in the animal and human health sectors.